Table 2.
Subject Demographics and Schizophrenia Characteristics
| |
RCT |
|
|||
|---|---|---|---|---|---|
| |
Ziprasidone |
Placebo |
OLE |
||
| Male | Female | Male | Female | Total | |
| n | 109 | 84 | 62 | 28 | 221 |
| Age (years) | |||||
| Mean±SD | 15.2±1.4 | 15.3±1.3 | 15.4±1.5 | 15.5±1.3 | 15.3±1.4 |
| Race, n (%) | |||||
| White | 62 (56.9) | 54 (64.3) | 43 (69.4) | 17 (60.7) | 140 (63.3) |
| Black | 10 (9.2) | 7 (8.3) | 2 (3.2) | 0 | 11 (5.0) |
| Asian | 21 (19.3) | 17 (20.2) | 12 (19.4) | 5 (17.9) | 44 (19.9) |
| Hispanic | 6 (5.5) | 3 (3.6) | 1 (1.6) | 2 (7.1) | 9 (4.1) |
| Other | 10 (9.2) | 3 (3.6) | 4 (6.5) | 4 (14.3) | 17 (7.7) |
| Ethnicity, n (%) | |||||
| Hispanic/Latino | 15 (13.8) | 6 (7.1) | 3 (4.8) | 6 (21.4) | 25 (11.3) |
| Not Hispanic | 94 (86.2) | 78 (92.9) | 59 (95.2) | 22 (78.6) | 196 (88.7) |
| Weight (kg) | |||||
| Mean±SD | 61.4±15.1 | 61.0±16.1 | 66.1±15.8 | 60.1±15.1 | 61.7±14.5 |
| Range | 30.0–106.0 | 38.5–126.8 | 37.0–106.4 | 31.5–105.0 | 31.5–105.0 |
| Height (cm) | |||||
| Mean±SD | 167.5±10.8 | 161.5±7.9 | 170.5±9.2 | 161.8±9.1 | 165.7±10.0 |
| Range | 123.0–190.0 | 143.0–180.3 | 148.0–186.7 | 139.0–178.0 | 123.0–190.0 |
| Schizophrenia, paranoid type (n) | 127 | 57 | 139 | ||
| Duration of current episode (months) | |||||
| Mean (range) | 9.6 (0–96) | 9.2 (0–84) | 9.4 (0–84) | ||
| Number of prior episodes | |||||
| Mean (range) | 1.1 (0–6) | 1.2 (0–8) | 1.1 (0–8) | ||
OLE, open-label extension; RCT, randomized controlled trial.